Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients
J. Clin. Invest. Renee C. Tschumper, et al. 118:306 doi:10.1172/JCI32625 [Go to this article.]

Figure 1
TTT analysis of UM B-CLL IGHV1-69 patients. (A) TTT is not significantly different when comparing UM IGHV1-69 B-CLL patients with all other UM B-CLL patients. (B) UM IGHV1-69 low Rai risk B-CLL patients do not have a significantly different TTT when compared with all other UM low Rai risk B-CLL patients.